Gilead Sciences to invest $300m in VC-backed Tizona Therapeutics

Gilead Sciences Inc has agreed to invest $300 million in Tizona Therapeutics, a clinical-stage immunotherapy company.

21 July 2020•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare M&A Deals Briefs